Inhibition of cyclin D1 enhances sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 5355-5363

  Su, Huafang ^a   Jin, Xiance ^a   Shen, Lanxiao ^a   Fang, Ya ^a   Fei, Zhenghua ^a   Zhang, Xuebang ^a   Xie, Congying ^a   Chen, Xiaolei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cyclin D1; Epithelial mesenchymal transition; Esophageal cancer; Radioresistance

Indexed keywords

CYCLIN D1; SMALL INTERFERING RNA; CADHERIN; RADIOSENSITIZING AGENT;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGUS CANCER; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; RADIOSENSITIVITY; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; ESOPHAGEAL NEOPLASMS; GENETICS; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

CADHERINS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RNA, SMALL INTERFERING;

EID: 84946781434     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4393-z     Document Type: Article

References (33)

1. Conteduca V, Sansonno D, Ingravallo G, Marangi S, Russi S, Lauletta G, et al. Barrett’s esophagus and esophageal cancer: an overview. Int J Oncol. 2012;41:414–24.
2. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598–606.
3. Linkous AG, Yazlovitskaya EM. Novel radiosensitizing anticancer therapeutics. Anticancer Res. 2012;32:2487–99.
4. Josson S, Sharp S, Sung SY, Johnstone PA, Aneja R, Wang R, et al. Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. J Oncol 2010;2010.232831
5. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22:194–207.
6. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.
7. Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013;341:63–7.
8. Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, Tajima K, et al. Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci U S A. 2012;109:2760–5.
9. Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014;16:864–75.
10. Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 2014;31:56–66.
11. Ghahhari NM, Babashah S. Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015;26:S0959–8049.
12. Kim E, Youn H, Kwon T, Son B, Kang J, Yang HJ, et al. PAK1 tyrosine phosphorylation is required to induce epithelial-mesenchymal transition and radioresistance in lung cancer cells. Cancer Res. 2014;74:5520–31.
13. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558–72.
14. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. Cell Physiol. 2009;220:292–6.
15. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell. 2009;36:469–76.
16. Shimura T, Kakuda S, Ochiai Y, Nakagawa H, Kuwahara Y, Takai Y, et al. Acquired radioresistance of human tumor cells by DNA-Pk/Akt/Gsk3beta-mediated cyclin D1 overexpression. Oncogene. 2010;29:4826–37.
17. Peng G, Cao RB, Li YH, Zou ZW, Huang J, Ding Q. Alterations of cell cycle control proteins SHP1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cells. Mol Med Rep. 2014;10:1709–16.
18. Jiao J, Huang L, Ye F, Shi M, Cheng X, Wang X, et al. Cyclin D1 affects epithelial-mesenchymal transition in epithelial ovarian cancer stem cell-like cells. Onco Targets Ther. 2013;6:667–77.
19. Tobin NP, Sims AH, Lundgren KL, Lehn S, Landerg G. Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer. 2011;11:417.
20. Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G, et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell. 2007;18:4615–24.
21. Su H, Jin X, Zhang X, Xue S, Deng X, Shen L, et al. Identification of microRNAs involved in the radioresistance of esophageal cancer cells. Cell Biol Int. 2014;38:318–25.
22. Su H, Jin X, Zhang X, Zhao L, Lin B, Li L, et al. FH535 increases the radiosensitivity and reverses epithelial-to-mesenchymal transition of radioresistant esophageal cancer cell line KYSE-150R. J Transl Med. 2015;13:104.
23. Cheng G, Zhang L, Lv W, Dong C, Wang Y, Zhang J. Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression. Med Oncol. 2015;32:439.
24. Williams JR, Zhang Y, Zhou H, Gridley DS, Koch CJ, Russell J, et al. A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. Int J Radiat Biol. 2008;84:253–64.
25. Williams JR, Zhang Y, Zhou H, Russell J, Gridley DS, Koch CJ, et al. Genotype-dependent radiosensitivity: clonogenic survival, apoptosis and cell-cycle redistribution. Int J Radiat Biol. 2008;84:151–64.
26. Belyaev IY. Radiation-induced DNA, repair foci: spatio-temporal aspects of formation, application for assessment of radiosensitivity and biological dosimetry. Mutat Res. 2010;704:132–41.
27. Kothari V, Mulherkar R. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma. Anticancer Res. 2012;32:121–8.
28. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci. 2004;117(Pt 11):2173–81.
29. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011;474:230–4.
30. Li Z, Chen K, Jiao X, Wang C, Willmarth NE, Casimiro MC, et al. Cyclin D1 integrates estrogen-mediated DNA damage repair signaling. Cancer Res. 2014;74:3959–70.
31. Gan GN, Eagles J, Keysar SB, Wang G, Glogowska MJ, Altunbas C, et al. Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers. Cancer Res. 2014;74:7024–36.
32. Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, et al. E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 2011;9:392–7.
33. Ju X, Casimiro MC, Gormley M, Meng H, Jiao X, Katiyar S, et al. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res. 2014;74:508–19.